Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Is India Falling Behind Its Neighbors In Attracting Clinical Research?

This article was originally published in The Pink Sheet Daily

Executive Summary

During the USA-India Chamber of Commerce biopharma summit, participants discussed the pros and cons of doing research in India, and pointed to key policy issues that must be resolved to spur more clinical trials.

You may also be interested in...

Indian Govt Move To Scrutinize MNC Investments In Indian Firms Could have "Chilling" Effect

MUMBAI - The Indian government has decided to route all foreign direct investments in existing Indian companies via the Foreign Investment Promotion Board, a surprising move that could have far-reaching implications on big ticket M&As in the country's pharmaceutical industry

Supreme Court Judge Recused From Glivec Patent Case In India

MUMBAI - A strongly worded letter of appeal signed by prominent IP lawyers and health activists to India's minister of law and Justice Salman Khurshid led to the surprise recusal of Supreme Court Judge Dalveer Bhandari from the controversial and long-pending Glivec (imatinib) patentability case in India

Building Trust, Technology Competence Can Boost Partnering Prospects For Indian, U.S. Companies

MUMBAI - In the run up to the annual U.S.-India BioPharma & Healthcare Summit, June 23 in Boston, PharmAsia News sat down with key industry players to discuss the state of the pharma industry in India. In the first part of this series, Boston Consulting Group provided a sneak preview of a report commissioned by the USA-India Chamber of Commerce that will be released at the summit ( 'Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For 'Niche Busters' And Stem Cells,' PharmAsia News, May 23, 2011 ). In the second story, PharmAsia News' India bureau spoke with Biogen Idec SVP Gunther Winkler, who discussed the big biotech's strategy in India and important policy decisions facing the Indian government ( 'Biogen's MS Drugs Ride High In India, Backed By Special Pricing, Awareness Building And Pharmacovigilance,' PharmAsia News, June 13, 20110.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts